MARISSA CARIGNAN: Open Payments
NPI 1407265978 · MANCHESTER, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,357 in 174 payments from 20 companies in 2025. Trend: 2023 $3,679 · 2024 $4,309 · 2025 $4,357
Food & beverage: $4,117Education: $240
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 25 | $822 |
| ABBVIE INC. | 28 | $544 |
| Janssen Biotech, Inc. | 11 | $373 |
| Amgen Inc. | 14 | $357 |
| Arcutis Biotherapeutics, Inc. | 12 | $303 |
| Regeneron Healthcare Solutions, Inc. | 7 | $266 |
| PFIZER INC. | 13 | $234 |
| GENZYME CORPORATION | 9 | $230 |
| LEO Pharma Inc. | 11 | $200 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $198 |
Products named: Bimzelx, DUPIXENT, TREMFYA, OTEZLA, SKYRIZI, Zoryve, CIBINQO, RINVOQ.
Industry payments across CT — which companies pay providers there.
